许刚，校聘教授，博士生导师， 2022年7月全职引进至安徽医科大学基础医学院微生物教研室。主要从事感染与免疫研究，在Cell Res，Signal Transduct Target Ther，Cell Discov，Cell, Nat Med等杂志发表SCI论文30余篇，以第一/通讯（含共同）发表SCI论文17篇，累计影响因子超过300。主持国家和省市级项目4项，累计经费340万元。

教育经历

2013.09-2017.01   中科院上海有机所生物与化学交叉研究中心  博士

2010.09-2013.07   第二军医大学微生物实验室                          硕士

2006.09-2010.07   中国农业大学农学与生物技术学院                本科

工作经历

2022.07-至今         安徽医科大学基础医学院微生物教研室         校聘教授

2019.06-2022.06   深圳市第三人民医院                       助理研究员/特聘副研究员

2017.05-2019.06   深圳市第三人民医院                                     博士后

1. 国家重点研发计划（子任务），2021YFC2300100，新冠病毒等呼吸道病毒感染和传播特性研究，2021/12-2021/11，150/2957万元，在研，主持；

2. 国家自然基金青年项目，82101857，RIPK1调控重症新冠肺炎炎症因子风暴的机制研究，2022/1/1-2024/12/31，30万元，在研，主持；

3. 深圳市科技创新委员会（合作课题），JSGG20220602140801003，抗疫专2022036 基于人工智能开发新靶点或新结构抗新冠病毒口服药物，2022/5-2023/5，150/600万元，在研，主持；

4. 广东省基础与应用基础研究基金委员会-面上项目，2019A1515011072，寨卡病毒感染激活PARP-1介导的细胞死亡机制研究，2019/10-2022/9，10万元，已结题，主持。

1. G. Xu*, Y. Li*, S. Zhang*, H. Peng*, Y. Wang*, D. Li, T. Jin, Z. He, Y. Tong, C. Qi, G. Wu, K. Dong, J. Gou, Y. Liu, T. Xiao, J. Qu, L. Li^#, L. Liu^#, P. Zhao^#, Z. Zhang^#, J. Yuan^#, SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Res 31, 1230-1243 (2021) 

2. G. Xu*, Y. Wu*, T. Xiao*, F. Qi*, L. Fan*, S. Zhang, J. Zhou, Y. He, X. Gao, H. Zeng, Y. Li, Z. Zhang, Multiomics approach reveals the ubiquitination-specific processes hijacked by SARS-CoV-2. Signal Transduct Target Ther 7, 312 (2022).

3. G. Xu*, F. Qi*, H. Li*, Q. Yang, H. Wang, X. Wang, X. Liu, J. Zhao, X. Liao, Y. Liu, L. Liu, S. Zhang^#, Z. Zhang^#, The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov 6, 73 (2020).

4. G. Xu*, F. Qi*, H. Wang, Y. Liu, X. Wang, R. Zou, J. Yuan, X. Liao, Y. Liu, S. Zhang^#, Z. Zhang^#, The Transient IFN Response and the Delay of Adaptive Immunity Feature the Severity of COVID-19. Front Immunol 12, 816745 (2021).

5. G. Xu*, Y. Liu*, M. Liao*, J. Gou*, X. Wang, J. Yuan, W. Liu, G. Zhou^#, S. Zhang^#, L. Liu^#, Z. Zhang^#, Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVID-19. Clin Transl Med 10, e224 (2020).

6. G. Xu, Y. Liu, H. Li^#, L. Liu^#, S. Zhang^#, Z. Zhang^#, Dissecting the human immune system with single cell RNA sequencing technology. J Leukoc Biol 107, 613-623 (2020).  

7. G. Xu*^#, S. Li*, X. Liu, P. Gao, X. Chen, H. Wang, M. Zhang, Y. Yang, G. F. Gao, F. Zhang^#, PARP-1 mediated cell death is directly activated by ZIKV infection. Virology 537, 254-262 (2019).

8. G. Xu*, F. Yang*, C. L. Ding*, L. J. Zhao, H. Ren, P. Zhao, W. Wang^#, Z. T. Qi^#, Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma. Mol Cancer 13, 216 (2014).

9. G. Xu*, F. Yang*, C. L. Ding*, J. Wang, P. Zhao, W. Wang^#, H. Ren^#, MiR-221 accentuates IFNs anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 462-463, 343-350 (2014). 3.513/Q3

10. X. Gao*, S. Zhang*, J. Gou*, Y. Wen, L. Fan, J. Zhou, G. Zhou, G. Xu^#, Z. Zhang^#, Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. J Infect,  (2022).  

11. C. Sui*, T. Xiao*, S. Zhang, H. Zeng, Y. Zheng, B. Liu, G. Xu^#, C. Gao^#, Z. Zhang^#, SARS-CoV-2 NSP13 Inhibits Type I IFN Production by Degradation of TBK1 via p62-Dependent Selective Autophagy. J Immunol 208, 753-761 (2022) 

12. F. Qi*, G. Xu*, X. Liao, F. Wang, J. Yuan, H. Wang, X. Wang, L. Liu, S. Zhang^#, Z. Zhang^#, ScRNA-seq revealed the kinetic of nasopharyngeal immune responses in asymptomatic COVID-19 carriers. Cell Discov 7, 56 (2021).

13. L. Luo*, W. Liang*, J. Pang*, G. Xu*, Y. Chen*, X. Guo, X. Wang, Y. Zhao, Y. Lai, Y. Liu, B. Li, B. Su, S. Zhang, M. Baniyash, L. Shen, L. Chen, Y. Ling, Y. Wang, Q. Liang, H. Lu^#, Z. Zhang^#, F. Wang^#, Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. Cell Discov 7, 89 (2021).

14. X. Wang*, G. Xu*, X. Liu*, Y. Liu, S. Zhang^#, Z. Zhang^#, Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection. Cell Mol Immunol 18, 2313-2324 (2021).

15. H. Shan*, J. Liu*, J. Shen*, J. Dai*, G. Xu*, K. Lu, C. Han, Y. Wang, X. Xu, Y. Tong, H. Xiang, Z. Ai, G. Zhuang, J. Hu, Z. Zhang^#, Y. Li^#, L. Pan, L^#. Tan^#, Development of potent and selective inhibitors targeting the papain-[like] protease of SARS-CoV-2. Cell Chem Biol 28, 855-865 e859 (2021).

16. C. L. Ding*, G. Xu*, H. Ren, L. J. Zhao, P. Zhao, Z. T. Qi^#, W. Wang^#, HCV infection induces the upregulation of miR-221 in NF-kappaB dependent manner. Virus Res 196, 135-139 (2015).

17. W. Wang*, G. Xu*, C. L. Ding, L. J. Zhao, P. Zhao, H. Ren, Z. T. Qi, All-trans retinoic acid protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating collagen 8A2. FEBS J 280, 1308-1319 (2013).

18. M. Liao*, Y. Liu*, J. Yuan*, Y. Wen, G. Xu, J. Zhao, L. Cheng, J. Li, X. Wang, F. Wang, L. Liu, I. Amit^#, S. Zhang^#, Z. Zhang^#, Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 26, 842-844 (2020).

19. P. Bost*, A. Giladi*, Y. Liu*, Y. Bendjelal, G. Xu, E. David, R. Blecher-Gonen, M. Cohen, C. Medaglia, H. Li, A. Deczkowska, S. Zhang, B. Schwikowski, Z. Zhang^#, I. Amit^#, Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell 181, 1475-1488 e1412 (2020).  ……

（*共同第一作者，#共同通讯作者）